obesity drug news today glp-1 october 27 2025 Massachusetts cuts coverage for 460K public workers and retirees, jeopardizing care and risking higher long-term health costs. Learn more GLP‑1 real‑world data for obesity:

Overall, therapeutic inertia was observed in 38.0% of the study population

If your healthcare team determines a medication hold is appropriate, the duration should be individualized based on your specific medication, dosing frequency, and clinical factors

Farxiga is the brand name for dapagliflozin, an oral tablet used to treat type 2 diabetes, heart failure, and chronic kidney disease

This isn't just about weightit's about getting your life back.

As experts continue to study the impact that GLP-1s have on health outcomes, state budgets, peoples lives and out-of-pocket costs, it is expected that the drugs will remain a topic of conversation among state lawmakers, Medicaid agencies, stakeholder groups and many others during the coming 2025 legislative session